![](//s1.studylibfr.com/store/data-gzf/f2070b2f24da817f5a14bfd32498dd68/1/003770073.htmlex.zip/bg5.jpg)
S. DANAN, D. CHAO UA T, G. BELANGE, S. RASCOVSCKI
6- COLLINS ON M.P., TYRELE CJ., HUTTON C.
Osteoporosis occuring on two patients receiving LHRH
analogue for carcinoma of the prostate.
Calcif. Tissue Int., 1994,54,327-328.
7- COL VARD D.S., ERICKSON E.F., KEETING P.E. et coll.
Identification of androgen receptors in normal human
osteoblast like cells.
Proc. Nat. Acad. Sei. USA, 1989, 88, 854-857.
8- DEL TOMBE L, PRIER A., FRANÇON A.et coll.
Agonistes de la GnRH et ostéoporose vertébrale chez
l' homme. Deux observations.
Ann. Méd. Int., 1995, 146,284-286.
9- DEVOGELAER LP., DONNEZ 1., CLERCK X. F.,
NAGANT DE DEUX CHAINES C.
Action of various regimens of implants of the LH RH analogue
buserelin on bone metabolism.
J. Bane Miner. Res., 1989,4,suppl.l,1l13.
10- DEVOGELAER J.P., NAGANT DE DEUX CHAINES C.,
CLERCK X.F., DONNEZ J.
Etfects of goserelin implants of LH RH analogue on lumbar
and hip BMD, as studied by the Dexa technique.
Calcif. Tissue Int. 1991,48, suppl. l, A, 80.
11- ERICKSON S., ERICKSSON A., STEGE R.,
CARLSTROM K.
Bone minerai density in patients with prostatic cancer treated
with orchidectomy and with estrogens.
Calcif. Tissue Int., 1995,57,97-99.
12- FINKELKSTEIN J.S., KLIBANSKI A., SCHAEFER E.H.
et coll.
Parathyroid hormone for the prevention of bone loss induced
by estrogen deficiency.
New Engl. J. Med., 1994,331,1618-1623.
13- FRASER 1.S.
Relationship between gonadotrophin releasing hormone
analogue therapy and bone loss: a review.
Reprod. Fert. Dev1op., 1991,3,61-70.
14- GALDRA Y D., WEISMAN Y., JACCARD N et coll.
Decreased bone density in elderly men treated with the
gonadotrophin-releasing hormon agonist (D-TRP6-GnRH).
J. Clin. End. Bane Metabol., 1993, 76, 288-290.
15- GUNDMUNDSSON J.A., LJUNGHALL S., BERGQUIST
C. et coll.
Increased bone turnover du ring gonadotrophine releasing
hormone superagonist induced ovulation inhibition.
J. Clin. End. Metab., 1987,65,159-163.
16- HAMED H., FOGELMAN L, FENTIMAN 1.S.
Effect of LH RH analogue on bone metabolism in patients with
mastalgia.
ln Osteoporosis. Chiristiansen C. Overgard R. ed.
Copenhague, 1990,3 vol., 1675-1676.
17- JOHAN SEN J.S., RIIS B.J., HASSAGER c., MOON M.
et coll.
The effect of gonadotropin-releasing hormone agonist analog
(Naferelin) on bon metabolism.
J. Clin. End. Metab., 1988,67,701-706.
18- MAILLEFERT LF., SIBILIA 1., KUNTZ LL.,
TAVERNIER C.
Gonadotrophin-releasing hormone agonists indu ce
osteoporosis.
Br.J. Rheumatol., 1994,33,1199-1200.
19 - MASAHASHI T., NEGORA Y., ASAI M. et coll.
Bone minerai content in premonopausal women treated with
gonadotrophin releasing hormone analogue.
Acta Obst. Gynaecol. Japon, 1992,44,577-580.
270
20- MURPHY S., KHA W K.T., CASSIDY A., CAMPTON lE.
Sex hormones and bone minerai density in elderly men.
Bone and Mineral. 1992,20,133-140.
21- PARVISI SJ., GUNBERG C.M., JENSEN P.S. et coll.
Elevated serum osteocalcin in women with endometriosis.
1Bone Min. Res., 1988,3 (suppl. 1),159 (abstract 364).
22- REVILLA R., REVILLA H., HERNANDEZ ER et coll.
Evidence that the loss of bone mass induced by GnRH agonists is
not totaly recovered.
Maturitas, 1995,22,145-150.
23- RICO H., ARMANZ F., REVILLA M. et coll.
Total and regional bone minerai content in women treated with
GnRH agonists.
Calcif. Tissue Int., 1993,52,354-357.
24- RIIS B.L, CHRISTIANSEN C., JOHANSEN J.S.,
JACOBSEN J.
Is it possible to prevent bone loss in young women treated with
Luteinizing Hormone releasing Hormone agonists ?
J. Clin. End. Metab., 1990,70,920-924.
25- ROUX c., PELISSIER C., LISTRAT V. et coll.
Bone loss during gonadotrophine releasing hormone agonist
treatment and use of nasal calcitonin.
Ostéoporosis Int., 1995,5,185-190.
26- SCHARLA S.H., MINNE H.W., WAIBEL- TREBER S. et coll.
Bone mass reduction after estrogen deprivation by long acting
gonadotropin-releasing hormone agonist and it's relation to pre-
treatment serum concentrations of 1,25 dihydroxy vitamin D3.
J. Clin. End. Metab., 1990, 70, 1055-1061.
27- SCIALLI A. R., JESTILA KJ., SIMON JA
Leueoprolide acetate and bone minerai density measured by
quantitative digitized radiography.
Fert. Steril., 1993,59,674-676.
28- STEPAN n., LACKMAN M., ZVERINA S. et ail.
Castrated men exhibit bone loss: effect of calcitonin treatment on
indices of bone remodeling.
J. Clin. Bane Metab., 1989,69,523-527.
29- SUGIMITO A.K., HODSMAN A.B., NISKER JA
Long term gonadotropin releasing hormone agonist with standard
postmenopausal estrogen replacement failed to prevent vertebral
bone loss in premenopausal women.
Fert. Steril., 1993,60,674-676.
30- TOBIAS J.H., CHAMBERS T.J., GALLAGHER A.
Effect of administration and subsequent cessation of Buserelin on
cancellous bone of female rats.
J. Bone Min. Res., 1994, ]2,1919-1925.
31- TOURLIERE D., VIALA J.F., BENHAMOU c.L.
Ostéoporose aux analogues de la LH RH chez un homme traité
pour cancer de la prostate.
Rev. Rhum., 1992,59,604.
32- TUMMON IS, ALI A., PEPPING ME, RADW ANSKA E. et
coll.
Bone minerai density in women with endometriosis before and
during ovarian suppression with gonadotropin releasing hormone
agonists or danazol.
Fertil. Steril. 1988,49, 792-796.
33- VENDERSCHEWEN D., BOUILLON R.
Androgens and bone.
Calcif. Tissue Int., 1995,56,341-344.
34- WAIBEL-TREBER S., MINNE H.W., SCHARLA S.H. et
coll.
Reversible bone loss in women treated with GnRH agonists for
endometriosis and uterine leiomyoma.
Human Reprod., 1989,4,384-388.